In the largest SMARCA4-mutated survival analysis in this review (N = 407), the authors determined that class 1 truncating mutations were the strongest independent factor for significantly worse OS for NSCLC patients [8]. Here, SMARCA4 is linked to non-small cell lung carcinoma.